| Name | EB-47 |
| Description | EB-47 mimics the substrate NAD+ and extends from the nicotinamide to the adenosine subsite.EB-47, a potent and selective PARP-1/ARTD-1 inhibitor with an IC50 value of 45 nM, shows modest potency against ARTD5 with an IC50 value of 410 nM. |
| In vitro | The inhibitory effect of EB-47 on CdPARP and HsPARP was 0.86 and 1.0uM with IC50 value respectively, and the inhibitory effect on CdPARP was over 50%[1]. |
| In vivo | EB-47, at a concentration of 2 μM for a duration of 5 days, reduces the number of embryo implantation sites and the quantity of blastocysts observed on day 5. PARP1 is involved in the embryo implantation process[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 22.5 mg/mL (41.86 mM), Sonication is recommended.
H2O : 100 mg/mL (186.04 mM), Sonication is recommended.
10% DMSO+90% Saline : 2.25 mg/mL (4.19 mM), Solution.
|
| Keywords | PARP1 | EB-47 | EB47 | EB 47 | ARTD1/PARP1 | ARTD-1 |
| Inhibitors Related | Taurodeoxycholate sodium salt | BGP-15 | Niraparib tosylate monohyrate | 7-Methylguanine | 3-Aminobenzamide | XAV-939 | Niraparib | AZ9482 | RMC-7977 | Olaparib | Benzamide | OUL35 |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Post-Translational Modification Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
